澳大利亚为患有致命脑肿瘤的儿童推出个性化的 mRNA疫苗试验。 Australia launches trial of personalized mRNA vaccines for children with deadly brain tumors.

在澳大利亚的8家医院启动了针对脑癌严重儿童的一项里程碑式的针对脑癌儿童个人性化的MRNA疫苗试验,对象是约70名患有罕见、高等级肿瘤的病人,这些肿瘤包括中脊腺瘤和弥漫性中脊髓灰质瘤。 A landmark personalized mRNA vaccine trial for children with aggressive brain cancers has launched in eight Australian hospitals, targeting around 70 patients with rare, high-grade tumors like medulloblastoma and diffuse midline glioma. 研究人员将利用每个儿童独特的肿瘤遗传学,在8至10周内制作定制疫苗,目的是训练免疫系统,以对抗癌症。 Using each child’s unique tumor genetics, researchers will create custom vaccines within eight to ten weeks, aiming to train the immune system to fight cancer. 这项为期四年的研究由昆士兰大学Brandon Wainwright教授牵头,涉及多个机构,将评估安全和有效性,预期在一年内取得早期结果。 The four-year study, led by Professor Brandon Wainwright of the University of Queensland and involving multiple institutions, will assess safety and effectiveness, with early results expected within a year. 这场试验为生存前景不佳的儿童带来了新的希望,因为脑癌仍然是导致澳大利亚儿童癌症相关死亡的主要原因,每年约有40人死亡。 The trial offers new hope for children facing poor survival prospects, as brain cancer remains the leading cause of cancer-related deaths in Australian children, with about 40 deaths annually.